Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed

Jerusalem, May 8, 2026 - Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma A

First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular application process Enrollment of all 88 patients completed in the ReSTART trial, a U.S. multicenter pivotal study evaluating Alpha DaRT® for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC), for which the Alpha DaRT has received Breakthrough Device Desig

First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at the world-renowned Pancreas Institute of the University of Verona The study is the first Alpha DaRT pancreatic cancer protocol worldwide to permit both endoscopic ultrasound (EUS)-guided and percutaneous delivery of Alpha DaRT sources, expanding the spectrum of access alternatives available to physicians including interventional radiologists, interventional oncologis

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Alpha Tau Announces Presentation of New Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT® Pancreatic Cancer Studies

ACAPELLA first Patient April 2026

- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 patients - - Study explores Alpha DaRT combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma – - This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with s

Jerusalem, March 31, 2026 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world’s premier international gastroenterology conference . This marks the first time that clinical result